Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Barr's ibuprofen

Executive Summary

Generic firm is first to receive post-1962 ANDA approval for Rx ibuprofen. During week of July 22, FDA approved ANDAs for 400 mg and 600 mg doses. Whslr. prices are: $6.39 for 400 mg 100s; $28.34 for 400 mg 500s; $8.84 for 600 mg 100s; $39.73 for 600 mg 500s. Boots attempted to block marketing, arguing in New York City Federal Court that Barr infringed on its patent by testing the drug before the ANDA/patent law became effective. Court issued a temporary restraining order July 25; however the order was overturned July 26.

You may also be interested in...



Fujifilm Demonstrates Health Specialism With European HealthTech Spinout

From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics. 

Financing Quarterly Statistics, Q1 2024

During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.

Helping Organizations Deliver On KPIs And Giving Staff A Voice

ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS008676

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel